durvalumab + enfortumab vedotin

**Durvalumab + enfortumab vedotin** is an investigational combination of two distinct oncology drugs used for the perioperative treatment of patients with muscle invasive bladder cancer, particularly those who are ineligible for or refuse cisplatin-based chemotherapy. **Durvalumab** is a fully human anti-PD-L1 monoclonal antibody (immune checkpoint inhibitor), blocking the programmed cell death ligand 1, thereby enhancing T-cell ability to detect and destroy cancer cells. **Enfortumab vedotin** is an antibody-drug conjugate that targets Nectin-4, a protein highly expressed in urothelial cancer cells, and delivers monomethyl auristatin E (MMAE), a cytotoxic microtubule-disrupting agent. This approach combines immune modulation with targeted cytotoxicity. The combination is being evaluated in phase 3 clinical trials (e.g., the VOLGA study) for its efficacy and safety compared to current standards of care for muscle invasive bladder cancer, especially for cisplatin-ineligible or cisplatin-refusing populations[1][3].

Brand names

Imfinzi + Padcev

Other names

MEDI4736 + enfortumab vedotindurvalumab + enfortumab vedotin-ejfv